Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Florian Eichler, Christine Duncan, Patricia L. Musolino, Troy C. Lund, Ashish O. Gupta, Satiro De Oliveira, Adrian J. Thrasher, Patrick Aubourg, Jörn‐Sven Kühl, Daniel J. Loes, Hernán Amartino, Nicholas Smith, Juliana Folloni Fernandes, Caroline Sevin, Raman Sankar, Shaun A. Hussain, Paul Gissen, Jean‐Hugues Dalle, Uwe Platzbecker, Gerald Downey, Elizabeth McNeil, Laura A. Demopoulos, Andrew C. Dietz, Himal L. Thakar, Paul J. Orchard, David A. Williams
Abstract
BACKGROUND: complementary DNA, is being tested in persons with cerebral adrenoleukodystrophy. METHODS: In a phase 2-3 study, we evaluated the efficacy and safety of eli-cel therapy in boys with early-stage cerebral adrenoleukodystrophy and evidence of active inflammation on magnetic resonance imaging (MRI). The primary efficacy end point was survival without any of six major functional disabilities at month 24. The secondary end points included overall survival at month 24 and the change from baseline to month 24 in the total neurologic function score. RESULTS: A total of 32 patients received eli-cel; 29 patients (91%) completed the 24-month study and are being monitored in the long-term follow-up study. At month 24, none of these 29 patients had major functional disabilities; overall survival was 94%. At the most recent assessment (median follow-up, 6 years), the neurologic function score was stable as compared with the baseline score in 30 of 32 patients (94%); 26 patients (81%) had no major functional disabilities. Four patients had adverse events that were directly related to eli-cel. Myelodysplastic syndrome (MDS) with excess blasts developed in 1 patient at month 92; the patient underwent allogeneic hematopoietic stem-cell transplantation and did not have MDS at the most recent follow-up. CONCLUSIONS: At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, respectively.).